DNA topoisomerases: Essential enzymes and lethal targets

Annual Review of Pharmacology and Toxicology

Volumn 34, Issue , 1994, Pages 191-218

  Chen, Allan Y ^a   Liu, Leroy F ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

anticancer drug; DNA damage; drug resistance; groove binder; intercalator

Indexed keywords

10,11 METHYLENEDIOXYCAMPTOTHECIN; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 9 AMINO 10,11 METHYLENEDIOXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; AMONAFIDE; AMSACRINE; ANTINEOPLASTIC AGENT; BATRACYLIN; BULGAREIN; CAMPTOTHECIN; CAMPTOTHECIN 11; CHROMOMYCIN A3; CLEROCIDINE; DACTINOMYCIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ED 110; ELLIPTICINE; ETOPOSIDE; GENISTEIN; GYRASE INHIBITOR; HOE 33342; INTERCALATING AGENT; MITHRAMYCIN; MITOXANTRONE; NOGALAMYCIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CELL CYCLE; DNA DAMAGE; DRUG RESISTANCE; DRUG TARGETING; HUMAN; MAMMAL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0028174984     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.34.040194.001203     Document Type: Review

References (199)

1. Wang JC. 1971. Interaction between DNA and Escherichia coli protein omega. J. Mol. Biol. 55:523-33
2. Depew RE, Liu LF, Wang JC. 1978. Interaction between DNA and E. coli protein omega: the formation of a complex between single-stranded DNA and omega protein. J. Biol. Chem. 253:511-18
3. Champoux JJ, Dulbecco R. 1972. An activity from mammalian cells that untwists superhelical DNA-a possible swivel for DNA replication. Proc. Natl. Acad. Sci. USA 69:143-46
4. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. 1976. An enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. USA 73:3872-76
5. DiNardo S, Voelkel KA, Sternglanz R, Reynolds AE, Wright A. 1982. Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes. Cell 31:43-51
6. Liu LF, Wang JC. 1987. Supercoiling of the DNA template during transcription. Proc. Natl. Acad. Sci. USA 84: 7024-27
7. Wu H-Y, Shyy SH, Wang JC, Liu LF. 1988. Transcription generates positively and negatively supercoiled domains in the template. Cell 53:433-40
8. Tsao Y-P, Wu H-Y, Liu LF. 1989. Transcription-driven supercoiling of DNA: direct biochemical evidence from in vitro studies. Cell 56:111-18
9. Liu LF, Liu CC, Alberts BM. 1979. T4 DNA topoisomerase. A new ATP-dependent enzyme essential for the initiation of T4 bacteriophage DNA replication. Nature 281:456-61
10. Stetler GL, King FJ, Huang WM. 1979. T4 DNA-delay proteins, required for specific DNA replications, from a complex that has ATP-dependent DNA topoisomerase activity. Proc. Natl. Acad. Sci. USA 76:3737-41
11. Liu LF. 1980. DNA strand passing and the function of type II DNA topoisomerases. In Mechanistic Studies of DNA Replication and Genetic Recombination. ICN-UCLA Symp. Mol. Cell. Biol., Vol. 19, ed. BM Alberts, 68:817-31. New York: Academic. 1003 pp.
12. Hsieh TS, Brutlag D. 1980. ATP dependent DNA Topoisomerase from D. melanogaster reversibly catenates duplex DNA rings. Cell 21:115-25
13. Baldi MI, Benedetti P, Mattoccia E, Tocchini-Valentini GP. 1980. In vitro catenation and decatenation of DNA and a novel eukaryotic ATP-dependent Topoisomerase. Cell 20:461-67
14. Miller KG, Miller KG, Liu LF, Englund PT. 1981. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J. Biol. Chem. 256:9334-39
15. Wang JC, Liu LF. 1979. DNA topoisomerases. Enzymes that catalyze the concerted breaking and rejoining of DNA bonds. In Molecular Genetics, ed. JH Taylor, 3:65-88. New York: Academic
16. Srivenugopal KS, Lockshon D, Morris DR. 1984. Escherichia coli DNA topoisomerase III: purification and characterization of a new type I enzyme. Biochemistry 23:1899-906
17. Kim RA, Wang JC. 1992. Identification of the yeast TOP3 gene product as a single strand-specific DNA topoisomerase. J. Biol. Chem. 267:17178-85
18. Wallis JW, Chrebet G, Brodsky G, Rolfe M, Rothstein R. 1989. A hyper-recombination mutation in S. cerevisiae identifies a novel eukaryotic topoisomerase. Cell 58:409-19
19. Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H. 1990. New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404
20. Kato J, Suzuki H, Ikeda H. 1992. Purification and characterization of DNA topoisomerase IV in Escherichia coli. J. Biol. Chem. 267:25676-84
21. Slesarev AI, Stetter KO, Lake JA, Gellert M, Krah R, Kozyavkin SA. 1993. DNA topoisomerase V is a relative of eukaryotic topoisomerase I from a hyperthermophilic prokaryote. Nature 364:735-37
22. Nash HA. 1981. Integration and excision of bacteriophage: the mechanism of conservative site specific recomination. Annu. Rev. Genet. 15: 143-66
23. Weisberg RA, Landy A. 1983. Site-specific recombination in phage lamda. In Lamda II, ed. RW Hendrix, JW Roberts, FW Stahl, RA Weisberg, pp. 211-50. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press
24. Kitts P, Richet E, Nash HA. 1984. λ Integrative recombination: supercoiling, synapsis, and strand exchange. Quant. Biol. 9:735-44
25. Richet E, Abcarian P, Nash HA. 1986. The interaction of recombination proteins with supercoiled DNA: defining the role of supercoiling in Lambda integrative recombination. Cell 46: 1011-21
26. Castell SE, Halford SE. 1989. DNA supercoiling determines the activation energy barrier for site specific recombination by TN21 resolvase. Nucleic Acids Res. 17:7045-58
27. Droge P, Cozzarelli NR. 1989. Recombination of knotted substrates by Tn3 resolvase. Proc. Natl. Acad. Sci. USA 86:6062-66
28. Liu LF, Liu CC, Alberts BM. 1980. Type II DNA topoisomerases. Enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell 19:697-707
29. Cozzarelli NR. 1980. DNA gyrase and the supercoiling of DNA. Science 207: 953-60
30. Gellert M. 1981. DNA topoisomerases. Annu. Rev. Biochem. 50:879-910
31. Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa J. 1977. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. USA 74:4772-76
32. Sugino A, Peebles CL, Kruezer KM, Cozzarelli NR. 1977. Mechanism of action of nalidixic acid: purification of E. coli nal A gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci. USA 74:4767-71
33. Shen LL, Mitscher LA, Sharma PN, O'Donnell TJ, Chu DWT, et al. 1989. Mechanism of inhibition of DNA gyrase by quinolone antibacterials - A cooperative drug-DNA binding model. Biochemistry 28:3886-94
34. Shen LL. 1993. Molecular mechanism of DNA gyrase inhibition by quinolone antibacterial agents. In Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy, ed. T Andoh, H Ikeda, M Oguro, pp. 177-86. Boca Raton, Fla: CRC Press
35. Tewey KM, Rowe TC, Yang L, Halligan BC, Liu LF. 1984. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466-68
36. Nelson EM, Tewey KM, Liu LF. 1984. Mechanism of antitumor drugs. Poisoning of mammalian DNA topoisomerase II on DNA by an antitumor drug m-AMSA. Proc. Natl. Acad. Sci. USA 81:1361-65
37. Tewey KM, Chen GL, Nelson EM, Liu LF. 1984. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259: 9182-87
38. Liu LF. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-75
39. Liu LF, D'Arpa P. 1992. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Important Adv. Oncol. 1992:79-89
40. Andoh T, Ikeda H, Oguro, M, eds. 1993. Molecular biology of DNA topoisomerases and its application to chemotherapy, Boca Raton, Fla: CRC Press. 377 pp.
41. Champoux JJ, Conaughy BL. 1976. Purification and characterzation of the DNA untwisting enzyme from rat liver. Biochemistry 15:4638-42
42. D'Arpa P, Machlin PS, Ratrie H III, Rothfield NF, Cleveland DW, Earnshaw WC. 1988. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc. Natl. Acad. Sci. USA 85:2543-47
43. Juan C-C, Hwang J, Liu AA, Whang-Peng J, Knutsen T, et al. 1988. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc. Natl. Acad. Sci. USA 85:8910-13
44. Champoux JJ. 1990. Mechanistic aspects of type-I topoisomerases. In DNA Topology and Its Biological Effects, ed. NR Cozzarelli, JC Wang, pp. 217-42. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press
45. Champoux JJ. 1977. Strand breakage by the DNA untwisting enzyme results in covalent attachment of the enzyme to DNA. Proc. Natl. Acad. Sci. USA 74:3800-4
46. Champoux JJ. 1978. Mechanism of the reaction catalyzed by the DNA untwisting enzyme: attachment of the enzyme to 3′-terminus of the nicked DNA. J. Mol. Biol. 118:441-46
47. Been MD, Burgess RR, Champoux JJ. 1984. Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res. 12:3097-4014
48. Edwards KA, Halligan BD, Davis JL, Nevera NL, Liu LF. 1982. Recognition sites of eukaryotic DNA topoisomerase I. DNA nucleotide sequencing analyses of topo I cleavage sites on SV40 DNA. Nucleic Acids Res. 10:2565-76
49. Champoux JJ, McCoubrey WK Jr, Been MD. 1984. DNA structural features that lead to strand breakage by eukaryotic type-I topoisomerase. Cold Spring Habor Symp. Quant. Biol. 49: 435-42
50. Halligan BD, Davis JL, Edwards KA, Liu LF. 1982. Intra-and intermolecular strand transfer by Hela DNA topo isomerase I. J. Biol. Chem. 257:3995-4000
51. Been MD, Champoux JJ. 1980. Breakage of single-stranded DNA by rat liver nicking-closing enzyme with the formation of a DNA-enzyme complex. Nucleic Acids Res. 8:6129-42
52. Been MD, Champoux JJ. 1981. DNA breakage and closure by rat liver type I topoisomerase: separation of the half-reactions by using a single-stranded DNA substrate. Proc. Natl. Acad. Sci. USA 78:2883-87
53. Yang L, Wold MS, Li JJ, Kelly TJ, Liu LF. 1987. Roles of DNA topoisomerases in SV40 DNA replication in vitro. Proc. Natl. Acad. Sci. USA 84:950-54
54. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, et al. 1984. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc. Natl. Acad. Sci. USA 81:6958-62
55. Stewart AF, Herrera RE, Nordheim A. 1990. Rapid induction of C-fos transcription reveals quantitative linkage of RNA polymerase-II and DNA topoisomerase-I enzyme activities. Cell 60:141-49
56. Zhang H, Wang JC, Liu LF. 1988. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. USA 85:1060-64
57. Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D. 1993. DNA topoisomerase 1 is involved in both repression and activation of transcription. Nature 365:227-32
58. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, et al. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88:3888-90
59. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. 1970. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 54:461-70
60. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. Part I 56:515-21
61. Hertzberg RP, Caranfa MJ, Holdern KG, Jakas DR, Gallagher G, et al. 1989. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase 1 and biological activity. J. Med. Chem. 32:715-20
62. Bosmann HB. 1970. Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria or E. coli. Biochem. Biophy. Res. Commun. 41:1412-20
63. Horwitz SB, Chang C-K, Grollman AP. 1971. Studies on camptothecin: effects on nucleic acid and protein synthesis. Mot. Pharmacol. 7:632-44
64. Horwitz MS, Horwitz SB. 1971. Intracellular degradation of hela and adenovirus type 2 DNA induced by camptothecin. Biochem. Biophys. Res. Commun. 45:723-27
65. Kessel D. 1971. Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochim. Biophys. Acta 246:225-32
66. Kessel D, Bosmann HB, Lohr K. 1972. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochim. Biophys. Acta 269:210-16
67. Wu RS, Kumar A, Warner JR. 1971. Ribosome formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis. Proc. Natl. Acad. Sci. USA 68:3009-14
68. Abelson HT, Penman S. 1972. Selective interruption of high molecular weight RNA synthesis in HeLa cells by camptothecin. Nature 237:144-46
69. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. 1972. Action of camptothecin on mammalian cells in culture. Cancer Res. 32:2643-50
70. Horwitz SB, Horwitz MS. 1973. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 33:2834-36
71. Hsiang Y-H, Lihou MG, Liu LF. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-82
72. Covey JM, Jaxel C, Kohn KW, Pommier Y. 1989. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase-I. Cancer Res. 49:5016-22
73. D'Arpa P, Beardmore C, Liu LF. 1990. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50:6919-24
74. Hsiang Y-H, Hertzberg R, Hecht S, Liu LF. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-78
75. Hsiang Y-H, Liu LF. 1988. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1722-26
76. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, et al. 1987. Characterization of a mammalian mutant with a camptothecin resistant DNA topo-isomerase I. Proc. Natl. Acad. Sci. USA 84:5565-69
77. Nitiss J, Wang JC. 1988. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA 85:7501-5
78. Zhang H, D'Arpa P, Liu LF. 1990. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 2:23-27
79. Tsao Y-P, Russo A, Nyamuswa G, Silber R, Liu LF. 1993. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 53:1-8
80. Tsao Y-P, D'Arpa P, Liu LF. 1992. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res. 52:1823-29
81. Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B, et al. 1991. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res. 51:6636-42
82. McSheehy PM, Gervasoni M, Lampasona V, Erba E, D'Incalci M. 1991. Studies of the differentiation properties of camptothecin in the human leukaemic cells K562. Eur. J. Cancer 27: 1406-11
83. Ling YH, Tseng MT, Nelson JA. 1991. Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a DNA topoisomerase I inhibitor. Differentiation 46:135-41
84. Aller P, Rius C, Mata F, Zorrilla A, Cabanas C, et al. 1992. Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res. 52:1245-51
85. Giovanella BC, Stehlin JS, Wall WE, Wani MC, Nicholas AW, et al. 1989. DNA topoisomerase I-targeted chemotherapy of human colon cancer in Xenografts. Science 246:1046-48
86. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJJ, et al. 1992. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 52:3980-87
87. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, et al. 1993. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res. 53:1577-82
88. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, et al. 1993. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between nontumorigenic and tumorigenic cells in vitro. Int. J. Cancer 53:863-71
89. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, et al. 1991. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 51:6039-44
90. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. 1992. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F. 104864), a new camptothecin analogue. Cancer Res. 52:2268-78
91. Hwong CL, Chen MS, Hwang J. 1989. Phorbol ester transiently increases topoisomerase I mRNA levels in human skin frbrosblasts. J. Biol. Chem. 264: 14923-26
92. Wani MC, Nicholas AW, Manikumar G, Wall ME. 1987. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J. Med. Chem. 30: 1774-79
93. Hsiang Y-H, Liu LF, Wall ME, Wani NC, Nicholas AW, et al. 1989. DNA topoisomerase 1 mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res. 49:4385-89
94. Yokokura T, Furuta T, Sawda S, Sugino E, Mutai M, et al. 1984. Antitumor activity of newly synthesized lactone ring-closed and water-soluble camptothecin derivative in mice. In Prof. Jpn. Cancer Assoc., 43rd Annu. Meet. Japan, p. 261
95. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. 1991. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51:4187-91
96. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, et al. 1992. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol. 10:16-20
97. Potmesil M, Giovanella BC, Wall ME, Liu LF, Silber R, et al. 1993. See Ref. 40, pp. 301-11
98. Trask DK, Muller MT. 1988. Stabilization of type I topoisomcrase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA 85:1417-21
99. Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, et al. 1990. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin-D on mammalian DNA topoisomerase-I and topoisomerase-II. Mol. Pharmacol. 38: 38-45
100. Chen AY, Yu C, Bodley A, Peng LF, Liu LF. 1993. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 53: 1332-37
101. Chen AY, Yu C, Gatto B, Liu LF. 1993. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA 90:8131-35
102. Fujii N, Yamashita Y, Saitoh Y, Nakano H. 1993. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein. J. Biol. Chem. 268:13160-65
103. Yamashita Y, Fujii N, Murakata C, Ashizawa T, Okabe M, et al. 1992. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31:12069-75
104. Yoshinari T, Yamada A, Uemura D, Nomura K, Arakawa H, et al. 1993. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res. 53: 490-94
105. Baguley BC. 1982. Nonintercalative DNA-binding antitumor compounds. Mol. Cell. Biochem. 43:167-81
106. Zimmer C, Wahnert U. 1986. Non-intercalating DNA-binding ligands: specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. Prog. Biophys. Mol. Biol. 47:31-112
107. Gilbert DE, Feigon J. 1991. Structural analysis of drug-DNA interactions. Curr. Opin. Struct. Biol. 1:439-45
108. Neidle S, Pearl LH, Skelly JV. 1987. DNA structure and perturbation by drug binding. Biochem. J. 243:1-13
109. Svejstrup JQ, Christiansen K, Andersen AH, Lund K, Westergaard O. 1990. Minimal DNA duplex requirements for topoisomerase-I-mediated cleavage in-vitro. J. Biol. Chem. 265:12529-35
110. Wu H-M, Crothers DM. 1984. The locus of sequence-directed and protein-induced DNA bending. Nature 308: 509-13
111. Jain SC, Sobell HM. 1972. Stereochemistry of actinomycin binding to DNA1 Refinement and further structural details of the actinomycin-deoxyguanosine crystal complex. J. Mol. Biol. 13:153-90
112. Sobell HM. 1973. The stereochemistry of actinomycin binding to DNA and its implication's in molecular biology. Prog. Nucleic Acids Res. Mol. Biol. 13:153-90
113. Scott EV, Zon G, Marzilli LG, Wilson WD. 1988. 2D NMR investigation of the binding of the anticancer drug actinomycin D to duplexd dATGCGCAT: conformational features of the unique 2:1 adduct. Biochemistry 27: 7940-51
114. Liaw Y-C, Gao Y-G, Robinson H, Marel GA, Boom JH, et al. 1989. Antitumor drug nogalamycin binds DNA in both grooves simultaneously: molecular structure of nogalamycin-DNA complex. Biochemistry 28:9913-18
115. Banville DL, Keniry MA, Kam M, Shafer RH. 1990. NMR studies of the interaction of chromomycin A3 with small DNA duplexes. Binding to GC-containing sequences. Biochemistry 29: 6521-34
116. Banville DL, Keniry MA, Shafer RH. 1990. NMR investigation of mithramycin A binding to d(ATGCAT)2: a comparative study with chromomycin A3. Biochemistry 29:9294-304
117. Gao X, Patel DJ. 1990. Chromomycin dimer-DNA oligomer complexes. Sequence selectivity and divalent cation specificity. Biochemistry 29:10940-56
118. Zhang X, Patel DJ. 1990. Solution structure of the nogalamycin-DNA complex. Biochemistry 29:9451-66
119. Liu LF. 1980. DNA strand passing and the function of type 11 DNA topoisomerases. In Genetic Recombination, ed. BM Alberts, pp. 817-31. New York: Academic
120. Halligan BD, Edward KA, Liu LF. 1985. Purification and characterization of a type II DNA topoisomcrase from bovine calf thymus. J. Biol. Chem. 260:2475-82
121. Yang L, Liu LF, Li JJ, Wold MS, Kelly TJ. 1986. The roles of DNA topoisomerase in SV40 DNA replication. UCLA Symp. Mol. Cell. Biol. 47:315-26
122. DiNardo S, Voelkel K, Sternglanz R. 1984. DNA topoisomerase II mutant of saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc. Natl. Acad. Sci. USA 81:2616-20
123. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, et al. 1987. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50: 917-25
124. Holm C, Stearns T, Botstein D. 1989. DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage. Mol. Cell. Biol. 9:159-68
125. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, et al. 1988. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome 17q21-22. Proc. Nail. Acad. Sci. USA 85:7177-81
126. Wang JC. 1987. Recent studies of DNA topoisomerases. Biochim. Biophys. Acta 909:1-9
127. Osheroff N, Shelton ER, Brutlag DL. 1983. DNA topoisomerase II from Drosophila melanogaster. J. Biol. Chem. 258:9536-43
128. Osheroff N. 1989. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol. Ther. 41:223-41
129. Corbett AH, Zechiedrich EL, Osheroff N. 1992. A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage. J. Biol. Chem. 267:683-86
130. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. 1983. Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258: 15365-70
131. Sander M, Hsieh TS. 1983. Double strand DNA cleavage by Type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem. 258:8421-28
132. Thomsen B, Bendixen C, Lund K, Andersen AH, Sorensen BS, Westergaard O. 1990. Characterization of the interaction between topoisomerase II and DNA by transcriptional footprinting. J. Mol. Biol. 215: 237-44
133. Roca J, Wang JC. 1992. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833-40
134. Lindsley JE, Wang JC. 1991. Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding. Proc. Natl. Acad. Sci. USA 88:10485-89
135. Lindsley JE, Wang JC. 1993. Study of allosteric communication between protomers by immunotagging. Nature 361:749-50
136. Lindsley JE, Wang JC. 1993. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J. Biol. Chem. 268:8096-8104
137. Hsiang Y-H, Liu LF. 1989. Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J. Biol. Chem. 264:9713-15
138. Tanabe K, Ikegami Y, Ishida R, Andoh T. 1991. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 51:4903-8
139. Ishida R, Miki T, Narita T, Yui R, Sato M, et al. 1991. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 51:4909-16
140. Ishimi Y, Ishida R, Andoh T. 1992. Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro. Mol. Cell. Biol. 12: 4007-14
141. Bodley AL, Liu LF, Israel M, Giuliani FC, Silber R, et al. 1989. DNA topoisomerase II-mediated Interaction of doxocrubicin and daunomycin congeners with DNA. Cancer Res. 49: 5969-78
142. D'Arpa P, Liu LF. 1989. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta 989: 163-77
143. Liu LF. 1989. Anticancer drugs that convert DNA topoisomerases into DNA damaging agents. In DNA Topology and Its Biological Effectd, ed. NR Cozzarelli, JC Wang. pp. 371-89. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press
144. Rowe TC, Chen GL, Hsiang Y-H, Liu LF. 1986. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46:2021-26
145. Pommier Y, Covey J, Kerrigan D, Mattes W, Markovits J, et al. 1987. Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomcrase II by 9-aminoacridines. Biochem. Pharmacol. 36:3477-86
146. Capranico G, Zunino F, Kohn KW, Pommier Y. 1990. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA affinity cytotoxicity. Biochemistry 29:562-69
147. Pommier Y, Capranico G, Orr A, Kohn KW. 1991. Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. J. Mol. Biol. 222:909-24
148. West C, Stratford IJ, Barrass N, Smith E. 1981. A comparison of adriamycin and mAMSA in vitro: cell lethality and SCE studies. Br. J. Cancer 44: 798-809
149. Deaven LL, Oka MS, Tobey RA. 1978. Cell-cycle specific chromosome damage following treatment of cultured Chinese hamster cells with 4′-(9-acridinylampo)methanesulfon-m-anisidide-HCI. J. Natl. Cancer Inst. 60:1155-61
150. Bae YS, Chiba M, Ohira M, Ikeda H. 1991. A shuttle vector for analysis of illegitimate recombination in mammalian cells: effects of DNA topoisomerase inhibitors on deletion frequency. Gene 101:285-89
151. Charron M, Hancock R. 1991. Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26. Chromosoma 100:97-102
152. Han YH, Austin MJ, Pommier Y, Povirk LF. 1993. Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J. Mol. Biol. 229:52-66
153. Bodley AL, Huang H-C, Yu C, Liu LF. 1993. Integration of simian virus 40 into cellular DNA occurs at or near topoisomerase II cleavage hot spots induced by VM-26 (teniposide). Mol. Cell. Biol. 13:6190-200
154. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Anna. Rev. Biochem. 62:385-427
155. Chen AY, Liu LF. 1993. Mechanisms of resistance to topoisomerase inhibitors. In Cancer Treatment and Research, ed. RF Ozols, L Goldstein. Norwell, Mass: Kluwer Academic. In press
156. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, et al. 1993. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl. Acad. Sci. USA 90:3231-35
157. Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, et al. 1988. Camptothecin-resistant mutants of Chinese hamster ovary cells containg a resistant form of topoisomerase I. Cancer Res. 48:6404-10
158. Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K, et al. 1988. Characterization of a camptothecin-resistant human DNA topoisomerase I. J. Biol. Chem. 263:3912-16
159. Tamura H, Kohchi C, Yamada R, Ikeda T, Koiwai O, et al. 1991. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase-I and identification of mutation sites. Nucleic Acids Res. 19: 69-75
160. Danks MK, Yalowich JC, Beck WT. 1987. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1297-301
161. Glisson BS, Sullivan DM, Gupta R, Ross WE. 1987. Mediation of multi-drug resistance in a chinese hamster ovary cell line by a mutant type II topoisomerase. Natl. Cancer Inst. Monogr. 4:89-93
162. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, et al. 1989. Characterization of an amsacrine-resistant line of human leukemia cells-evidence for a drug-resistant form of topoisomerase-II. J. Biol. Chem. 264: 16411-20
163. Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, et al. 1991. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions. Biochemistry 30: 4048-55
164. Bugg BY, Danks MK, Beck WT, Suttle DP. 1991. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA 88:7654-58
165. Kubota N, Kanzawa F, Nishio K, Takeda Y, Ohmori T, et al. 1992. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun. 188:571-77
166. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, et al. 1991. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 51:4729-31
167. Zwelling LA, Mitchell MJ, Satitpunwaycha P, Mayes J, Altschuler E, et al. 1992. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development. Cancer Res. 52:209-17
168. Lee MS, Wang JC, Beran M. 1992. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J. Mol. Biol. 223:837-43
169. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, et al. 1992. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem. Pharmacol. 44:937-45
170. Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, et al. 1993. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 53: 1373-79
171. Chan VT, Ng SW, Eder JP, Schnipper LE. 1993. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem. 268: 2160-65
172. Sullivan DM, Eskildsen LA, Groom KR, Webb CD, Latham MD, et al. 1993. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Mol. Pharmacol. 43:207-16
173. Andoh T, Tamura H, Kohchi C, Yamada R, Ikeda T, et al. 1993. Mechanism of camptothecin resistance in mammalian cells: mutation in topoisomerase I gene and its implication in enzymatic function. See Ref. 40, pp. 229-35
174. Gromova II, Kjeldsen E, Svejstrup JQ, Alsner J, Christiansen K, et al. 1993. Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res. 21:593-600
175. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. 1988. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21:71-74
176. Long BH, Wang L, Lorico A, Wang RC, Brattain MG, et al. 1991. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 51:5275-83
177. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M. 1991. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 51:3951-57
178. Odaimi M, Anderson BS, McCredie KB, Beran M. 1986. Drug sensitivity and cross-resistance of the 4′-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res. 46:3330-33
179. Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. 1989. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-Glycoprotein overexpression. Cancer Res. 49:4542-49
180. Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang J, et al. 1990. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem. 265:10060-80
181. DeJong S, Zijlstra JG, Devries EGE, Mulder NH. 1990. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 50:304-9
182. Wilson WR, Whitmore GF. 1981. Cell-cycle-stage specificity of 4′-(9-acridinylamino)methanesulfon-m-anisi dide(m-AMSA) and interaction with ionizing radiation in mammalian cell cultures. Radiat. Res. 87:121-36
183. Nitiss J, Wang JC. 1991. Yeast as a genetic system in the dissection of the mechanism of cell-killing by topoisomerase-targeting anticance drugs. In DNA Topoisomerase in Cancer, ed. P Milan, KW Kohn, pp. 77-90. New York: Oxford Univ. Press
184. Posada J, Vichi P, Tretton TR. 1989. Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res. 49:6634-39
185. Fine RL, Ratel J, Chabner BA. 1987. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc. Natl. Acad. Sci. USA 85:582-86
186. Corbett AH, Fernald AW, Osheroff N. 1993. Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation. Biochemistry 32:2090-97
187. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, et al. 1987. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. J. Biol. Chem. 262:16739-47
188. Austin CA, Sng JH, Patel S, Fisher LM. 1993 Novel HeLa topoisomerase II is the II-β isoform: complete coding sequence and homology with other type II topoisomcrases. Biochim. Biophys. Acta 1172:283-91
189. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, et al. 1989. Biochemical and pharmacological properties of P170 and P180 forms of topoisomerase-II. Biochemistry 28: 8154-60
190. Harker WG, Slade DL, Drake FH, Parr RL. 1991. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase-II β-isoform. Biochemistry 30:9953-61
191. Hochhauser D, Harris AL. 1993. The role of topoisomerase IIα and β in drug resistance. Cancer Treat Rev. 19:181-94
192. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. 1991. Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerasc II in NIH-3T3 cells. Cell Growth Differ. 2:209-14
193. Zini N, Martelli AM, Sabatelli P, Santi S, Negri C, et al. 1992. The 180-kDa isoform of topoisomerase II is localized in the nuclcolus and belongs to the structural elements of the nucleolar remnant. Exp. Cell Res. 200:460-66
194. Negri C, Chiesa R, Cerino A, Bestagno M, Sala C, et al. 1992. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170-and 180-kDa isozymes. Exp. Cell Res. 200:452-59
195. Negri C, Scovassi AI, Braghetti A, Guano F, Astaldi RG. 1993. DNA topoisomerase II β: stability and distribution in different animal cells in comparison to DNA topoisomerase I and II α. Exp. Cell Res 206:128-33
196. Chen AY, Yu C, Lee W-H, Peng LF, Liu LF. 1992. Menadione (vitamin K3) induces topoisomerase II-mediated DNA cleavage. Proc. Am. Assoc. Cancer Res. 33:2588 (Abstr.)
197. Luo Y, Ren YF, Chou TC, Chen AY, Yu C, et al. 1993. A structure-activity relationship study of batracylin analogues. Pharm. Res. 10:918-23
198. Nutter LM, Cheng AL, Hung H-L, Hsieh R-K, Ngo EO, et al. 1991. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem. Pharmacol. 41:1283-92
199. Plowman J, Paull KD, Atassi G, Harrison JSD, Dykes DJ, et al. 1988. Preclinical antitumor activity of batracylin (NSC. 320846). Invest. New Drugs 6:147-53